Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection
 
research article

Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection

Preynat-Seauve, O.
•
Schuler, P.
•
Contassot, E.
Show more
2006
Journal of Immunology

Dendritic cells (DC) are potent inducers of immune responses. DC have been shown to infiltrate tumors, but very little is known about the functional status of these naturally occurring tumor-infiltrating DC (TIDC). In this study, the status and function of TIDC from several types of mouse melanoma were investigated in detail. CD11c+/MHC II+ cells, consistent with a DC phenotype, were found in all of transplantable or spontaneous melanomas studied. These TIDC were predominantly myeloid (CD11c+/CD8alpha-/B220-) in nature with small numbers of plasmacytoid (CD11c+/B220+). TIDC had an intermediate maturation phenotype with some expression of costimulatory molecules and the capacity to take up particles. Upon culture overnight ex vivo, the TIDC markedly up-regulated the expression of costimulatory molecules and also increased IL-12 production. Importantly, such ex vivo-matured TIDC pulsed with OVA were able to migrate to lymph nodes, to activate naive OVA-specific CD4+ and CD8+ T cells, and to confer protection against a challenge with OVA-expressing tumor cells. In conclusion, melanomas are infiltrated by functional DC that can act as fully competent APC. These APC have the potential to be manipulated and may therefore represent a promising target for cancer immunotherapy.

  • Details
  • Metrics
Type
research article
DOI
10.4049/jimmunol.176.1.61
Author(s)
Preynat-Seauve, O.
Schuler, P.
Contassot, E.
Beermann, F.  
Huard, B.
French, L. E.
Date Issued

2006

Published in
Journal of Immunology
Volume

176

Issue

1

Start page

61

End page

67

Note

Louis Jeantet Skin Cancer Laboratory, Department of Pathology and Immunology, Geneva University Medical Center, Geneva, Switzerland. oliver.preynat-seauve@medecine.unige.ch

Editorial or Peer reviewed

REVIEWED

Written at

OTHER

EPFL units
GR-BEERMANN  
Available on Infoscience
January 10, 2008
Use this identifier to reference this record
https://infoscience.epfl.ch/handle/20.500.14299/16083
Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés